A Multicyclic Catalytic Network Enabling ROS Amplification, Metabolic Disruption, and Immune Modulation for Antitumor–Antibacterial Therapy
ACS Applied Materials & Interfaces · 12.11.2026
DOI: 10.1021/acsami.6c15932 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, online erschienen am 12.11.2026. Verfasst von Chao Ban und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry, China Pharmaceutical University, Nanjing211198, China. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, Joint Funds for the Innovation of Science and Technology of Fujian Province.
Abstract (Originalsprache)
Intratumoral bacteria are increasingly recognized as important regulators of tumor progression, immune suppression, and metastasis, whereas current therapeutic strategies remain insufficient to address the coupled tumor–bacteria microenvironment. Here, we report a multicyclic catalytic network (VBC-Net) that integrates alkaline polyoxovanadate with a Bi2WO6–CuSx p–n heterojunction for coordinated antitumor–antibacterial immunotherapy. Unlike conventional single-mechanism nanozymes, VBC-Net establishes interconnected catalytic cycles that sustain ROS amplification, oxygen activation, and glutathione depletion, thereby converting transient catalytic activity into persistent oxidative stress. Simultaneously, the alkaline microenvironment and Bi-associated interference with respiratory-chain-related processes may contribute to metabolic perturbation, coupling oxidative stress with metabolic disruption. VBC-Net is further associated with dendritic-cell maturation, enhanced T-cell infiltration, and pro-inflammatory immune modulation, suggesting remodeling of the tumor–bacteria–immune microenvironment. In murine 4T1 tumor and MRSA-infected models, VBC-Net achieves pronounced tumor suppression, bacterial clearance, reduced metastatic progression, and accelerated wound healing with good biocompatibility. This work establishes a multicyclic catalytic strategy for targeting complex tumor-associated ecosystems and provides a promising framework for antitumor–antibacterial therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Chemistry, China Pharmaceutical University, Nanjing211198, China.
- Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou350001, China.
- Phase I Clinical Trial Unit, Fujian Medical University Union Hospital, Fuzhou350001, China.
ORCID-Profile: Weiwei Guo
Förderung
- Fundamental Research Funds for the Central Universities
- Joint Funds for the Innovation of Science and Technology of Fujian Province
Zitieren
APA
Ban, C., Lin, H., Cheng, M., Chen, S., Hao, Z., Shen, Y., Sha, Y., Xue, Y., Feng, J., Chen, J., Guo, W., & Que, W. (2026). A Multicyclic Catalytic Network Enabling ROS Amplification, Metabolic Disruption, and Immune Modulation for Antitumor–Antibacterial Therapy. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.6c15932
Vancouver
Ban C, Lin H, Cheng M, Chen S, Hao Z, Shen Y, et al. A Multicyclic Catalytic Network Enabling ROS Amplification, Metabolic Disruption, and Immune Modulation for Antitumor–Antibacterial Therapy. ACS Applied Materials & Interfaces. 2026. doi:10.1021/acsami.6c15932
BibTeX
@article{Ban2026,
author = {Ban, Chao and Lin, Hailing and Cheng, Mingxin and Chen, Shuanglong and Hao, Ziteng and Shen, Yun and Sha, Yubin and Xue, Yangyin and Feng, Jinkang and Chen, Jiaxuan and Guo, Weiwei and Que, Wancai},
title = {A Multicyclic Catalytic Network Enabling ROS Amplification, Metabolic Disruption, and Immune Modulation for Antitumor–Antibacterial Therapy},
journal = {ACS Applied Materials & Interfaces},
year = {2026},
doi = {10.1021/acsami.6c15932}
}
EUVIMED